NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/18/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,438.19 mln
Float76.29 mln
Earnings Date03/31/2027
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
0.65
Highly suspicious
1-Year Forecast
47.12
Transformational upside
Relative Strength
10
/ 100
Significantly lagging
Debt / Equity
3.77
Highly leveraged
Pre-Tax Margin
-227%
Severely loss-making
Business Description
Founded in 2009 and based in Suzhou, China, Ascentage Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, chronic hepatitis B, and age-related conditions. The company has built a broad pipeline of investigational medicines that work by targeting specific proteins involved in tumor growth and cell survival, with several compounds currently advancing through clinical trials. Beyond drug development, Ascentage also engages in scientific research services, venture investment, and partnerships with pharmaceutical companies and research institutions worldwide.
